Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
Add more filters

Publication year range
1.
Lancet ; 385(9977): 1519-26, 2015 Apr 18.
Article in English | MEDLINE | ID: mdl-25612858

ABSTRACT

BACKGROUND: In adults with acute stroke, infections occur commonly and are associated with an unfavourable functional outcome. In the Preventive Antibiotics in Stroke Study (PASS) we aimed to establish whether or not preventive antimicrobial therapy with a third-generation cephalosporin, ceftriaxone, improves functional outcome in patients with acute stroke. METHODS: In this multicentre, randomised, open-label trial with masked endpoint assessment, patients with acute stroke were randomly assigned to intravenous ceftriaxone at a dose of 2 g, given every 24 h intravenously for 4 days, in addition to stroke unit care, or standard stroke unit care without preventive antimicrobial therapy; assignments were made within 24 h after symptom onset. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale and analysed by intention to treat. The primary analysis was by ordinal regression of the primary outcome. Secondary outcomes included death, infection rates, antimicrobial use, and length of hospital stay. Participants and caregivers were aware of treatment allocation but assessors of outcome were masked to group assignment. This trial is registered with controlled-trials.com, number ISRCTN66140176. FINDINGS: Between July 6, 2010, and March 23, 2014, a total of 2550 patients from 30 sites in the Netherlands, including academic and non-academic medical centres, were randomly assigned to the two treatment groups: 1275 patients to ceftriaxone and 1275 patients to standard treatment (control group). 12 patients (seven in the ceftriaxone group and five in the control group) withdrew consent immediately after randomisation, leaving 2538 patients available for the intention-to-treat-analysis (1268 in the ceftriaxone group and 1270 in the control group). 2514 (99%) of 2538 patients (1257 in each group) completed 3-month follow-up. Preventive ceftriaxone did not affect the distribution of functional outcome scores on the modified Rankin Scale at 3 months (adjusted common odds ratio 0·95 [95% CI 0·82-1·09], p=0·46). Preventive ceftriaxone did not result in an increased occurrence of adverse events. Overgrowth infection with Clostridium difficile occurred in two patients (<1%) in the ceftriaxone group and none in the control group. INTERPRETATION: Preventive ceftriaxone does not improve functional outcome at 3 months in adults with acute stroke. The results of our trial do not support the use of preventive antibiotics in adults with acute stroke. FUNDING: Netherlands Organization for Health Research and Development, Netherlands Heart Foundation, and the European Research Council.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Pneumonia/prevention & control , Stroke/complications , Stroke/therapy , Urinary Tract Infections/prevention & control , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Intention to Treat Analysis , Length of Stay , Male , Middle Aged , Netherlands , Pneumonia/diagnosis , Pneumonia/epidemiology , Prospective Studies , Quality-Adjusted Life Years , Recovery of Function , Treatment Outcome , Urinary Tract Infections/diagnosis , Urinary Tract Infections/epidemiology
2.
Eur J Haematol ; 97(3): 271-7, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26676382

ABSTRACT

BACKGROUND: Mortality prediction models of patients with a haematological malignancy admitted to an intensive care unit (ICU) do not include the presence of neutropenia and microbiology results. We performed a registry-based retrospective study of haematology patients admitted to the ICU to investigate the relation between neutropenia, microbiology results and outcome of these patients. METHODS: Neutropenia and microbiology culture results within 24 h before or after ICU admission of patients with a haematological malignancy admitted between 2004 and 2010 were described and analysed for association with 28-day mortality. RESULTS: We identified 234 individual patients with a current malignant haematological condition, of which 27% were neutropenic and 21% had a positive blood culture at admission. Most prevalent from blood cultured species were Escherichia coli and coagulase-negative staphylococci. The overall 28-day mortality was 38%. In patients with a positive blood culture but no neutropenia, 28-day mortality was 28% and in patients with neutropenia but without positive blood culture, it was 36%. The 28-day mortality of patients with both neutropenia and a positive blood culture was 55% with an adjusted (for APACHE-II score) hazard ratio (HR) of 1.8 (95%CI 1.0-3.4) compared to other hematologic patients admitted to the ICU. CONCLUSION: In patients with haematological malignancy admitted to the ICU, culture results are diverse. The combination of neutropenia and positive blood culture is associated with increased 28-day mortality. We suggest this could be of additional value when assessing mortality risk in this patient group.


Subject(s)
Hematologic Neoplasms/epidemiology , Infections/epidemiology , Infections/etiology , Intensive Care Units , Adult , Aged , Female , Hematologic Neoplasms/complications , Hematologic Neoplasms/mortality , Humans , Infections/diagnosis , Infections/mortality , Kaplan-Meier Estimate , Male , Middle Aged , Mortality , Netherlands , Neutropenia/complications , Neutropenia/epidemiology , Neutropenia/etiology , Outcome Assessment, Health Care , Registries , Retrospective Studies , Sepsis/diagnosis , Sepsis/epidemiology , Sepsis/etiology , Sepsis/mortality , Severity of Illness Index
3.
Clin Infect Dis ; 61(8): 1281-92, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26123933

ABSTRACT

BACKGROUND: Several countries consider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for adolescents. Representative information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-effectiveness of vaccination. Information on the relation between infecting meningococcal clonal complex (CC), disease course and outcome of IMD is scarce. METHODS: A retrospective study using Dutch surveillance data on IMD from June 1999 to June 2011. Clinical information was retrieved from hospital records. The effect of age, comorbidity, clinical manifestation, serogroup, and CC on disease course and outcome was assessed in multivariable analyses. Meningococcal CCs were assessed by multilocus sequence typing. RESULTS: Clinical information was retrieved for 879 IMD cases: 48% of patients presented with meningitis, 17% with septic shock, and 22% with septic shock plus meningitis. Development of septic shock was not related to CC or serogroup. Median (interquartile range) duration of hospital admission was 10 (8-13) days. Intensive care unit admittance (38%) was higher for patients aged ≥10 years and patients with septic shock (P-values ≤.001). Case-fatality rate (8%) and development of sequelae (29%) was dependent on age and clinical manifestation (P-values ≤.001) and not affected by comorbidity, CC, or serogroup. CONCLUSIONS: IMD still coincides with a considerable disease burden and mortality. Disease course and outcome depend mainly on age and clinical manifestation and less on meningococcal CC or serogroup.


Subject(s)
Meningitis, Meningococcal/epidemiology , Meningitis, Meningococcal/microbiology , Meningococcal Infections/epidemiology , Meningococcal Infections/microbiology , Neisseria meningitidis/classification , Shock, Septic/microbiology , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Comorbidity , Cost of Illness , Female , Hospitalization/statistics & numerical data , Humans , Incidence , Infant , Infant, Newborn , Male , Meningitis, Meningococcal/mortality , Meningococcal Infections/mortality , Meningococcal Infections/pathology , Meningococcal Vaccines , Middle Aged , Multilocus Sequence Typing , Neisseria meningitidis/genetics , Neisseria meningitidis/immunology , Netherlands/epidemiology , Retrospective Studies , Serogroup , Time Factors , Vaccination/statistics & numerical data , Young Adult
4.
Clin Infect Dis ; 59(9): 1216-21, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25069869

ABSTRACT

BACKGROUND: Vaccination with meningococcal serogroup C (MenC) conjugate (MCC) polysaccharide vaccines led to a substantial decline in MenC disease in the vaccinated and the unvaccinated population. The decline in the unvaccinated population can be explained by herd protection by reduced colonization of meningococci expressing the MenC capsule. The duration of such herd protection is unknown. METHODS: In a nationwide study from the Netherlands, we compared MenC invasive disease between 1998 and the introduction of MCC vaccination (2002) with that from 2002 to 2012, in age groups eligible and not eligible for vaccination. The proportions of isolates from clonal complexes with high serogroup C capsule expression rate during carriage (sequence type [ST] 11 and ST-8 complex) was compared between the pre- and postvaccination periods. RESULTS: A total of 814 patients with invasive MenC disease were included for analysis. There was a 99% decline in MenC disease in patients eligible for vaccination and a 93% decline in those not eligible. Thirty-six percent of the overall MenC reduction between the first and last 4 years of the observation period occurred in the unvaccinated population. Clonal complex was determined in 350 (43%) isolates. The proportion of cases caused by clonal complex ST-11 and ST-8 serogroup C meningococci decreased from 251 of 268 (94%) before, to 46 of 57 (81%) after MCC vaccine introduction (P = .004). CONCLUSIONS: Our findings provide further evidence that herd protection results from reduced carriage of virulent meningococci. Herd protection was responsible for >36% of MCC vaccine impact and lasted for ≥10 years.


Subject(s)
Immunity, Herd , Meningococcal Infections/epidemiology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cohort Studies , Female , Humans , Incidence , Infant , Male , Meningococcal Infections/microbiology , Meningococcal Vaccines/administration & dosage , Middle Aged , Multilocus Sequence Typing , Neisseria meningitidis, Serogroup C/classification , Neisseria meningitidis, Serogroup C/genetics , Netherlands/epidemiology , Young Adult
5.
BMC Infect Dis ; 13: 340, 2013 Jul 23.
Article in English | MEDLINE | ID: mdl-23879305

ABSTRACT

BACKGROUND: Sensorineural hearing loss is the most common sequela in survivors of bacterial meningitis (BM). In the past we developed a validated prediction model to identify children at risk for post-meningitis hearing loss. It is known that host genetic variations, besides clinical factors, contribute to severity and outcome of BM. In this study it was determined whether host genetic risk factors improve the predictive abilities of an existing model regarding hearing loss after childhood BM. METHODS: Four hundred and seventy-one Dutch Caucasian childhood BM were genotyped for 11 single nucleotide polymorphisms (SNPs) in seven different genes involved in pathogen recognition. Genetic data were added to the original clinical prediction model and performance of new models was compared to the original model by likelihood ratio tests and the area under the curve (AUC) of the receiver operating characteristic curves. RESULTS: Addition of TLR9-1237 SNPs and the combination of TLR2 + 2477 and TLR4 + 896 SNPs improved the clinical prediction model, but not significantly (increase of AUC's from 0.856 to 0.861 and from 0.856 to 0.875 (p = 0.570 and 0.335, respectively). Other SNPs analysed were not linked to hearing loss. CONCLUSIONS: Although addition of genetic risk factors did not significantly improve the clinical prediction model for post-meningitis hearing loss, AUC's of the pre-existing model remain high after addition of genetic factors. Future studies should evaluate whether more combinations of SNPs in larger cohorts has an additional value to the existing prediction model for post meningitis hearing loss.


Subject(s)
Hearing Loss, Sensorineural/genetics , Hearing Loss, Sensorineural/microbiology , Meningitis, Bacterial/complications , Meningitis, Bacterial/genetics , Models, Statistical , Area Under Curve , Chi-Square Distribution , Child , Child, Preschool , Cohort Studies , Female , Genetic Predisposition to Disease , Genotype , Humans , Infant , Male , Netherlands , Polymorphism, Single Nucleotide , ROC Curve , Retrospective Studies , Risk Factors
6.
Support Care Cancer ; 21(9): 2417-26, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23579946

ABSTRACT

PURPOSE: Infections are a major cause of morbidity and mortality in pediatric cancer patients. The aim of this study was to establish the microbiological spectrum and the susceptibility patterns of bacteremia-causing bacteria in pediatric cancer patients with febrile neutropenia in relation to the use of prophylactic and empirical antibiotics. METHODS: We analyzed positive blood cultures of pediatric cancer patients presenting with febrile neutropenia between 2004 and 2011 in Groningen and Amsterdam (the Netherlands) and in Bern (Switzerland), using different antibiotic prophylactic and empirical regimens. RESULTS: A total of 156 patients with 202 bacteremias, due to 248 bacteria species, were enrolled. The majority (73%) of bacteremias were caused by Gram-positive bacteria. Gram-negative bacteria, especially Pseudomonas aeruginosa, were observed significantly more often in Bern, where no fluoroquinolone prophylaxis was used. Ciprofloxacin-resistant bacteria were cultured more often from patients who did receive ciprofloxacin prophylaxis, compared to the patients who did not (57 versus 11%, p = 0.044). CONCLUSIONS: Gram-positive bacteria predominated in this study. We showed that the use of prophylactic antibiotics in pediatric cancer patients was associated with increased resistance rates, which needs further study. The strategy for empiric antimicrobial therapy for febrile neutropenia should be adapted to local antibiotic resistance patterns.


Subject(s)
Bacteremia/microbiology , Febrile Neutropenia/microbiology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Gram-Positive Bacteria/drug effects , Gram-Positive Bacterial Infections/drug therapy , Neoplasms/complications , Adolescent , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/mortality , Child , Child, Preschool , Drug Resistance, Bacterial , Febrile Neutropenia/mortality , Female , Fever/drug therapy , Fever/microbiology , Fever/mortality , Gram-Negative Bacteria/growth & development , Gram-Positive Bacteria/growth & development , Humans , Infant , Male , Microbial Sensitivity Tests , Neoplasms/drug therapy , Netherlands/epidemiology , Switzerland/epidemiology
7.
J Clin Microbiol ; 50(6): 1918-26, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22442325

ABSTRACT

A set of 300 Dutch Cryptococcus neoformans isolates, obtained from 237 patients during 1977 to 2007, was investigated by determining the mating type, serotype, and AFLP and microsatellite genotype and susceptibility to seven antifungal compounds. Almost half of the studied cases were from HIV-infected patients, followed by a patient group of individuals with other underlying diseases and immunocompetent individuals. The majority of the isolates were mating type α and serotype A, followed by αD isolates and other minor categories. The most frequently observed genotype was AFLP1, distantly followed by AFLP2 and AFLP3. Microsatellite typing revealed a high genetic diversity among serotype A isolates but a lower diversity within the serotype D set of isolates. One patient was infected by multiple AFLP genotypes. Fluconazole and flucytosine had the highest geometric mean MICs of 2.9 and 3.5 µg/ml, respectively, while amphotericin B (0.24 µg/ml), itraconazole (0.08 µg/ml), voriconazole (0.07 µg/ml), posaconazole (0.06 µg/ml), and isavuconazole (0.03 µg/ml) had much lower geometric mean MICs. One isolate had a high flucytosine MIC (>64 µg/ml), while decreased susceptibility (≥16 µg/ml) for flucytosine and fluconazole was found in 9 and 10 C. neoformans isolates, respectively.


Subject(s)
Cryptococcosis/epidemiology , Cryptococcosis/microbiology , Cryptococcus neoformans/classification , Cryptococcus neoformans/genetics , Genetic Variation , Molecular Typing , Mycological Typing Techniques , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/pharmacology , Cryptococcus neoformans/isolation & purification , Female , HIV Infections/complications , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Epidemiology , Netherlands/epidemiology , Serotyping , Young Adult
8.
Foodborne Pathog Dis ; 9(1): 37-46, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21988401

ABSTRACT

The emergence of plasmid-mediated multidrug resistance (MDR) among enteric bacteria presents a serious challenge to the treatment of bacterial infections in humans and animals. Recent studies suggest that avian Escherichia coli commonly possess the ability to resist multiple antimicrobial agents, and might serve as reservoirs of MDR for human extraintestinal pathogenic Escherichia coli (ExPEC) and commensal E. coli populations. We determined antimicrobial susceptibility profiles for 2202 human and avian E. coli isolates, then sought for associations among resistance profile, plasmid content, virulence factor profile, and phylogenetic group. Avian-source isolates harbored greater proportions of MDR than their human counterparts, and avian ExPEC had higher proportions of MDR than did avian commensal E. coli. MDR was significantly associated with possession of the IncA/C, IncP1-α, IncF, and IncI1 plasmid types. Overall, inferred virulence potential did not correlate with drug susceptibility phenotype. However, certain virulence genes were positively associated with MDR, including ireA, ibeA, fyuA, cvaC, iss, iutA, iha, and afa. According to the total dataset, isolates segregated significantly according to host species and clinical status, thus suggesting that avian and human ExPEC and commensal E. coli represent four distinct populations with limited overlap. These findings suggest that in extraintestinal E. coli, MDR is most commonly associated with plasmids, and that these plasmids are frequently found among avian-source E. coli from poultry production systems.


Subject(s)
Anti-Infective Agents/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli Infections/microbiology , Escherichia coli/genetics , Plasmids/genetics , Poultry Diseases/microbiology , Animals , Chickens , DNA, Bacterial/genetics , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Escherichia coli/pathogenicity , Feces/microbiology , Female , Genotype , Humans , Infant, Newborn , Meat/microbiology , Microbial Sensitivity Tests , Phylogeny , Replicon/genetics , Turkeys , Virulence Factors/genetics
9.
Clin Infect Dis ; 53(1): e1-7, 2011 Jul 01.
Article in English | MEDLINE | ID: mdl-21653293

ABSTRACT

BACKGROUND: Nontypeable (unencapsulated) strains of Haemophilus influenzae (ntHi) are usually involved in respiratory tract infections and otitis media but may also cause invasive disease. The epidemiology, the course of disease, and the outcome of ntHi invasive disease are not well established. For prevention, risk groups that might benefit from vaccination have to be defined. METHODS: All patients with ntHi invasive disease confirmed by culture of samples collected by the Netherlands Reference Laboratory for Bacterial Meningitis from 41 sentinel hospitals and representative of ∼45% of all Dutch hospitalized ntHi case patients over the period from 2001 through 2008 were included in the study. Data on clinical presentation, course of disease, and outcome as well as patient characteristics and comorbidity were retrospectively retrieved from hospital records. RESULTS: Clinical presentations of 396 cases included mainly invasive pneumonia (190 cases [48%]) and bacteremia without a clinical focus (75 cases [19%]). Comorbidities were present in 327 [83%] and immunodeficiency in 173 [44%] of all cases. The overall case fatality rate within the first month after diagnosis was 12% and the lowest (2%) was among patients aged 5-54 years. The highest extrapolated age-specific incidence rates occurred within the first 6 weeks of life (19.0 cases per 100,000 persons), concerning mostly prematurely born infants with bacteremia within 24 h after birth, and in the first year of life (5.6 cases per 100,000 persons). The highest rate in adults was among elderly patients aged >65 years (2.2 cases per 100,000 persons). CONCLUSIONS: This study provides a detailed overview of invasive ntHi disease cases in the Netherlands. Risk groups are prematurely born infants, elderly patients aged >65 years, and immunocompromised patients.


Subject(s)
Haemophilus Infections/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/complications , Bacteremia/diagnosis , Bacteremia/epidemiology , Child , Child, Preschool , Female , Haemophilus Infections/complications , Haemophilus Infections/diagnosis , Haemophilus influenzae/isolation & purification , Hospitalization/statistics & numerical data , Humans , Infant , Male , Middle Aged , Netherlands/epidemiology , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/epidemiology , Retrospective Studies , Sentinel Surveillance
10.
J Antimicrob Chemother ; 66(10): 2418-24, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21719471

ABSTRACT

BACKGROUND: Using data from an observational study in which the effectiveness of a guideline for eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage was evaluated, we identified variables that were associated with treatment failure. METHODS: A multivariate logistic regression model was performed with subgroup analyses for uncomplicated and complicated MRSA carriage (the latter including MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage) and for those treated according to the guideline (i.e. mupirocin nasal ointment and chlorhexidine soap solution for uncomplicated carriage, in combination with two oral antibiotics for complicated carriage). RESULTS: Six hundred and thirteen MRSA carriers were included, of whom 333 (54%) had complicated carriage; 327 of 530 patients (62%) with known complexity of carriage were treated according to the guideline with an absolute increase in treatment success of 20% (95% confidence interval 12%-28%). Among those with uncomplicated carriage, guideline adherence [adjusted odds ratio (OR(a)) 7.4 (1.7-31.7)], chronic pulmonary disease [OR(a) 44 (2.9-668)], throat carriage [OR(a) 2.9 (1.4-6.1)], perineal carriage [OR(a) 2.2 (1.1-4.4)] and carriage among household contacts [OR(a) 5.6 (1.2-26)] were associated with treatment failure. Among those with complicated carriage, guideline adherence was associated with treatment success [OR(a) 0.2 (0.1-0.3)], whereas throat carriage [OR(a) 4.4 (2.3-8.3)] and dependence in activities of daily living [OR(a) 3.6 (1.4-8.9)] were associated with failure. CONCLUSIONS: Guideline adherence, especially among those with complicated MRSA carriage, was associated with treatment success. Adding patients with extranasal carriage or dependence in daily self-care activities to the definition of complicated carriage, and treating them likewise, may further increase treatment success.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Local/therapeutic use , Carrier State/drug therapy , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/drug therapy , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Anti-Infective Agents, Local/administration & dosage , Asymptomatic Infections , Carrier State/microbiology , Chlorhexidine/administration & dosage , Chlorhexidine/therapeutic use , Female , Guideline Adherence , Humans , Logistic Models , Male , Methicillin Resistance , Middle Aged , Mupirocin/administration & dosage , Mupirocin/therapeutic use , Practice Guidelines as Topic , Staphylococcal Infections/microbiology , Treatment Failure
11.
J Antimicrob Chemother ; 66(10): 2409-17, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21719473

ABSTRACT

BACKGROUND: We evaluated the effectiveness of eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage in the Netherlands after the introduction of a guideline in 2006. The guideline distinguishes complicated (defined as the presence of MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage) and uncomplicated carriage (not meeting criteria for complicated carriage). Mupirocin nasal ointment and chlorhexidine soap solution are recommended for uncomplicated carriers and the same treatment in combination with two oral antibiotics for complicated carriage. METHODS: A prospective cohort study was performed in 18 Dutch centres from 1 October 2006 until 1 October 2008. RESULTS: Six hundred and thirteen MRSA carriers underwent one or more decolonization treatments during the study period, mostly after hospital discharge. Decolonization was achieved in 367 (60%) patients with one eradication attempt and ultimately 493 (80%) patients were decolonized, with a median time until decolonization of 10 days (interquartile range 7-43 days). Three hundred and twenty-seven (62%) carriers were treated according to the guideline, which was associated with an absolute increase in treatment success of 20% [from 45% (91/203) to 65% (214/327)]. CONCLUSIONS: Sixty percent of MRSA carriers were successfully decolonized after the first eradication attempt and 62% were treated according to the guideline, which was associated with an increased treatment success.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Local/therapeutic use , Carrier State/drug therapy , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/drug therapy , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Asymptomatic Infections , Carrier State/microbiology , Chlorhexidine/therapeutic use , Cohort Studies , Cross Infection/drug therapy , Cross Infection/microbiology , Female , Humans , Male , Middle Aged , Mupirocin/administration & dosage , Mupirocin/therapeutic use , Netherlands , Practice Guidelines as Topic , Staphylococcal Infections/microbiology , Treatment Outcome
12.
Emerg Infect Dis ; 16(5): 816-23, 2010 May.
Article in English | MEDLINE | ID: mdl-20409372

ABSTRACT

In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.


Subject(s)
Pneumococcal Infections/epidemiology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/therapeutic use , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Incidence , Infant , Middle Aged , Netherlands/epidemiology , Pneumococcal Infections/etiology , Pneumococcal Infections/physiopathology , Population Surveillance , Serotyping , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/isolation & purification , Time Factors , Treatment Outcome
13.
BMC Infect Dis ; 10: 259, 2010 Sep 03.
Article in English | MEDLINE | ID: mdl-20815866

ABSTRACT

BACKGROUND: Previously two prediction rules identifying children at risk of hearing loss and academic or behavioral limitations after bacterial meningitis were developed. Streptococcus pneumoniae as causative pathogen was an important risk factor in both. Since 2006 Dutch children receive seven-valent conjugate vaccination against S. pneumoniae. The presumed effect of vaccination was simulated by excluding all children infected by S. pneumoniae with the serotypes included in the vaccine, from both previous collected cohorts (between 1990-1995). METHODS: Children infected by one of the vaccine serotypes were excluded from both original cohorts (hearing loss: 70 of 628 children; academic or behavioral limitations: 26 of 182 children). All identified risk factors were included in multivariate logistic regression models. The discriminative ability of both new models was calculated. RESULTS: The same risk factors as in the original models were significant. The discriminative ability of the original hearing loss model was 0.84 and of the new model 0.87. In the academic or behavioral limitations model it was 0.83 and 0.84 respectively. CONCLUSION: It can be assumed that the prediction rules will also be applicable on a vaccinated population. However, vaccination does not provide 100% coverage and evidence is available that serotype replacement will occur. The impact of vaccination on serotype replacement needs to be investigated, and the prediction rules must be validated externally.


Subject(s)
Meningitis, Pneumococcal/complications , Meningitis, Pneumococcal/prevention & control , Nervous System Diseases/epidemiology , Nervous System Diseases/prevention & control , Vaccination/statistics & numerical data , Child , Child, Preschool , Computer Simulation , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Meningitis, Pneumococcal/epidemiology , Meningitis, Pneumococcal/immunology , Netherlands/epidemiology , Pneumococcal Vaccines/administration & dosage , Serotyping , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/isolation & purification
14.
Clin Infect Dis ; 49(2): e23-9, 2009 Jul 15.
Article in English | MEDLINE | ID: mdl-19522653

ABSTRACT

BACKGROUND: The Streptococcus pneumoniae polysaccharide capsule may be related to invasive pneumococcal disease (IPD) course. METHODS: We performed a retrospective cohort study with nationally representative surveillance data from 1075 hospitalized patients with IPD from the Netherlands from 1 June 2004 through 31 May 2006 in the prevaccination era. Serotypes were grouped according to invasive disease potential, rate of the most serious clinical syndromes of meningitis and bacteremia without focus, and case-fatality rates. Multivariable logistic regression analysis was performed to obtain odds ratios adjusted for baseline confounders for the association of serotypes and these outcomes, using the serotypes with the lowest rates as reference. RESULTS: IPD caused by serogroups with low invasive disease potential concerned meningitis or bacteremia without focus in 22% of cases, and 74% of patients had an underlying comorbidity. For highly invasive serogroups these figures were 10% (P < .01) and 56% (P < .01). Individual serotypes varied in the relative rate by which they caused meningitis or bacteremia without focus. Compared with the reference group composed of serotypes 1, 5, 7F, 15B, 20, and 33F, the group of serotypes 3, 19F, 23A, 16F, 6B, 9N, and 18C was associated with increased case-fatality rates (group adjusted odds ratio, 2.6; 95% confidence interval, 1.5-4.7). CONCLUSIONS: The serotype appeared to be independently associated with IPD severity in adults, which indicates that careful monitoring of IPD after implementation of conjugate vaccines is necessary.


Subject(s)
Pneumococcal Infections/microbiology , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/pathogenicity , Adult , Aged , Aged, 80 and over , Bacteremia/drug therapy , Bacteremia/epidemiology , Bacteremia/microbiology , Cohort Studies , Hospitalization , Humans , Meningitis, Pneumococcal/drug therapy , Meningitis, Pneumococcal/epidemiology , Meningitis, Pneumococcal/microbiology , Middle Aged , Netherlands/epidemiology , Pneumococcal Infections/drug therapy , Pneumococcal Infections/epidemiology , Prevalence , Retrospective Studies , Serotyping , Streptococcus pneumoniae/isolation & purification , Treatment Outcome , Virulence , Young Adult
15.
Ann Neurol ; 63(1): 90-7, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17823938

ABSTRACT

OBJECTIVE: To derive and validate a bedside risk score for adverse outcome in adults with bacterial meningitis. METHODS: We derived a score for the risk for an unfavorable outcome (Glasgow Outcome Scale score 1-4) by performing logistic regression analyses of data from a prospective cohort study (Dutch Meningitis Cohort; N = 696). A key set of independent prognostic variables was selected from 22 potential predictors. A nomogram based on these key variables was constructed to facilitate use in clinical practice. To validate this nomogram, we used data from our randomized controlled trial on adjunctive dexamethasone therapy in adults with bacterial meningitis (European Dexamethasone Study; N = 301). RESULTS: Unfavorable outcome occurred in 237 of 696 episodes (34%) in the Dutch Meningitis Cohort; 143 patients (21%) died. In the analysis, 6 of 22 variables that are routinely available within 1 hour after admission were robust enough for inclusion in the final risk score: age, heart rate, Glasgow Coma Scale score, cranial nerve palsies, a cerebrospinal fluid leukocyte count less than 1,000 cells/mm3, and gram-positive cocci in cerebrospinal fluid Gram's stain. The concordance index for the risk score was 0.84 (95% confidence interval, 0.80-0.87) in the original cohort and 0.81 (95% confidence interval, 0.74-0.87) in the external validation cohort (European Dexamethasone Study). INTERPRETATION: This bedside risk score can be used to identify patients with a high risk for unfavorable outcome in adults with bacterial meningitis within 1 hour after the initial presentation.


Subject(s)
Meningitis, Bacterial/diagnosis , Severity of Illness Index , Adult , Age Factors , Aged , Anti-Bacterial Agents/therapeutic use , Arrhythmias, Cardiac/epidemiology , Cerebrospinal Fluid/microbiology , Cohort Studies , Comorbidity , Cranial Nerve Diseases/epidemiology , Double-Blind Method , Early Diagnosis , Female , Humans , Male , Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/physiopathology , Middle Aged , Nomograms , Placebo Effect , Prognosis , Prospective Studies , Randomized Controlled Trials as Topic/statistics & numerical data , Regression Analysis , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
16.
BMC Infect Dis ; 9: 57, 2009 May 08.
Article in English | MEDLINE | ID: mdl-19426501

ABSTRACT

BACKGROUND: Hyperglycemia has been associated with unfavorable outcome in several disorders, but few data are available in bacterial meningitis. We assessed the incidence and significance of hyperglycemia in adults with bacterial meningitis. METHODS: We collected data prospectively between October 1998 and April 2002, on 696 episodes of community-acquired bacterial meningitis, confirmed by culture of CSF in patients >16 years. Patients were dichotomized according to blood glucose level on admission. A cutoff random non-fasting blood glucose level of 7.8 mmol/L (140 mg/dL) was used to define hyperglycemia, and a cutoff random non-fasting blood glucose level of 11.1 mmol/L (200 mg/dL) was used to define severe hyperglycemia. Unfavorable outcome was defined on the Glasgow outcome scale as a score <5. We also evaluated characteristics of patients with a preadmission diagnosis of diabetes mellitus. RESULTS: 69% of patients were hyperglycemic and 25% severely hyperglycemic on admission. Compared with non-hyperglycemic patients, hyperglycemia was related with advanced age (median, 55 yrs vs. 44 yrs, P < 0.0001), preadmission diagnosis of diabetes (9% vs. 3%, P = 0.005), and distant focus of infection (37% vs. 28%, P = 0.02). They were more often admitted in coma (16% vs. 8%; P = 0.004) and with pneumococcal meningitis (55% vs. 42%, P = 0.007). These differences remained significant after exclusion of patients with known diabetes. Hyperglycemia was related with unfavorable outcome in a univariate analysis but this relation did not remain robust in a multivariate analysis. Factors predictive for neurologic compromise were related with higher blood glucose levels, whereas factors predictive for systemic compromise were related with lower blood glucose levels. Only a minority of severely hyperglycemic patients were known diabetics (19%). The vast majority of these known diabetic patients had meningitis due to Streptococcus pneumoniae (67%) or Listeria monocytogenes (13%) and they were at high risk for unfavorable outcome (52%). CONCLUSION: The majority of patients with bacterial meningitis have hyperglycemic blood glucose levels on admission. Hyperglycemia can be explained by a physical stress reaction, the central nervous system insult leading to disturbed blood-glucose regulation mechanisms, and preponderance of diabetics for pneumococcal meningitis. Patients with diabetes and bacterial meningitis are at high risk for unfavorable outcome.


Subject(s)
Blood Glucose/analysis , Hyperglycemia/complications , Meningitis, Bacterial/complications , Adult , Aged , Community-Acquired Infections/complications , Diabetes Mellitus/blood , Glasgow Outcome Scale , Humans , Hyperglycemia/diagnosis , Meningitis, Bacterial/diagnosis , Middle Aged , Multivariate Analysis , Prevalence , Prognosis , Prospective Studies , Risk Factors , Young Adult
17.
Clin Infect Dis ; 47(5): e42-51, 2008 Sep 01.
Article in English | MEDLINE | ID: mdl-18643757

ABSTRACT

BACKGROUND: Patients may experience multiple episodes of bacterial meningitis. Information from large studies of recurrent meningitis is limited. We evaluated the incidence of recurrent bacterial meningitis and the distribution of causative organisms in The Netherlands. METHODS: Data for patients with bacterial meningitis were prospectively collected nationwide for the period 1988-2005. Recurrent meningitis was defined as an episode of meningitis that either occurred >or=28 days after a previous episode or occurred <28 days after a previous episode but was caused by a different pathogen or different subtype of the same pathogen. RESULTS: Of 18,915 patients, 202 (predominantly male) patients had recurrent bacterial meningitis (P< .01). Prevailing causative organisms were Streptococcus pneumoniae (40% of cases), Neisseria meningitidis (22%), and non-type b Haemophilus influenzae (9%). Pneumococci serotypes included in the heptavalent vaccine caused only 36% of cases of recurrent pneumococcal meningitis. The proportion of episodes caused by meningococcus serogroups W135, Y, and Z was higher among patients with recurrent meningitis than among those with nonrecurrent meningitis (odds ratio, 12.8), and the proportion caused by nontypeable and type f H. influenzae was also higher among patients with recurrent meningitis (odds ratio, 3.8 and 5.6, respectively). CONCLUSIONS: In The Netherlands, the prevalence of recurrent bacterial and fungal meningitis is low. The distribution of causative microorganisms differs between cases of recurrent meningitis and cases of nonrecurrent meningitis; this could be associated with vaccination.


Subject(s)
Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/microbiology , Meningitis, Fungal/epidemiology , Meningitis, Fungal/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Haemophilus influenzae/isolation & purification , Humans , Infant , Male , Middle Aged , Neisseria meningitidis/isolation & purification , Netherlands/epidemiology , Prospective Studies , Recurrence , Streptococcus pneumoniae/isolation & purification , Young Adult
18.
Medicine (Baltimore) ; 87(4): 185-192, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18626301

ABSTRACT

Meningococcal meningitis remains a life-threatening disease. Neisseria meningitidis is the leading cause of meningitis and septicemia in young adults and is a major cause of endemic bacterial meningitis worldwide. The Meningitis Cohort Study was a Dutch nationwide prospective observational cohort study of adults with community-acquired bacterial meningitis, confirmed by culture of cerebrospinal fluid, from October 1998 to April 2002. Patients underwent a neurologic examination at discharge, and outcome was graded with the Glasgow Outcome Scale. Serogrouping, multi-locus sequence typing, and susceptibility testing of meningococcal isolates were performed. The study identified 258 episodes of meningococcal meningitis in 258 patients. The prevalence of the classical triad of fever, neck stiffness, and change in mental status was low (70/258, 27%). When rash was added to the classical triad, 229 of 258 (89%) patients had at least 2 of 4 signs. Systolic hypotension was associated with rash (22/23 vs. 137/222, p = 0.002) and absence of neck stiffness (6/23 vs. 21/220, p = 0.05). Neuroimaging before lumbar puncture was an important cause of delay of therapy: antibiotics were not initiated before computed tomography (CT) scan in 85% of patients who underwent CT scan before lumbar puncture. Unfavorable outcome occurred in 30 of 258 (12%) patients, including a mortality rate of 7%. Neurologic sequelae occurred in 28 of 238 (12%) patients, particularly hearing loss (8%). Factors associated with sepsis and infection with meningococci of clonal complex 11 (cc11) are related with unfavorable outcome.


Subject(s)
Meningitis, Meningococcal/physiopathology , Neisseria meningitidis/genetics , Adult , Anti-Bacterial Agents/therapeutic use , Bacteriological Techniques , DNA, Bacterial/genetics , Female , Genotype , Glasgow Outcome Scale , Humans , Male , Meningitis, Meningococcal/therapy , Neisseria meningitidis/classification , Neisseria meningitidis/isolation & purification , Prevalence , Prospective Studies , Risk Factors , Sequence Analysis, DNA , Treatment Outcome
19.
Antimicrob Agents Chemother ; 52(5): 1850-1, 2008 May.
Article in English | MEDLINE | ID: mdl-18285470

ABSTRACT

We tested the activity of daptomycin against 76 Listeria monocytogenes isolates from cerebrospinal fluid by broth dilution and Etest methods. For the broth dilution method, the MIC range was 1.0 to 8.0 and the MIC at which 90% of the isolates tested were inhibited (MIC(90)) was 4.0 mg/liter. For the Etest method, the MIC range was 1.0 to 4.0 and the MIC(90) was 4.0 mg/liter. Presently, daptomycin cannot be recommended for the treatment of L. monocytogenes meningitis.


Subject(s)
Daptomycin/pharmacology , Listeria monocytogenes/drug effects , Listeriosis/cerebrospinal fluid , Anti-Bacterial Agents/pharmacology , Humans , Listeria monocytogenes/isolation & purification , Listeriosis/microbiology , Microbial Sensitivity Tests , Netherlands
20.
Appl Environ Microbiol ; 74(22): 7043-50, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18820066

ABSTRACT

Since extraintestinal pathogenic Escherichia coli (ExPEC) strains from human and avian hosts encounter similar challenges in establishing infection in extraintestinal locations, they may share similar contents of virulence genes and capacities to cause disease. In the present study, 1,074 ExPEC isolates were classified by phylogenetic group and possession of 67 other traits, including virulence-associated genes and plasmid replicon types. These ExPEC isolates included 452 avian pathogenic E. coli strains from avian colibacillosis, 91 neonatal meningitis E. coli (NMEC) strains causing human neonatal meningitis, and 531 uropathogenic E. coli strains from human urinary tract infections. Cluster analysis of the data revealed that most members of each subpathotype represent a genetically distinct group and have distinguishing characteristics. However, a genotyping cluster containing 108 ExPEC isolates was identified, heavily mixed with regard to subpathotype, in which there was substantial trait overlap. Many of the isolates within this cluster belonged to the O1, O2, or O18 serogroup. Also, 58% belonged to the ST95 multilocus sequence typing group, and over 90% of them were assigned to the B2 phylogenetic group typical of human ExPEC strains. This cluster contained strains with a high number of both chromosome- and plasmid-associated ExPEC genes. Further characterization of this ExPEC subset with zoonotic potential urges future studies exploring the potential for the transmission of certain ExPEC strains between humans and animals. Also, the widespread occurrence of plasmids among NMEC strains and members of the mixed cluster suggests that plasmid-mediated virulence in these pathotypes warrants further attention.


Subject(s)
Chickens/microbiology , Escherichia coli Infections/veterinary , Escherichia coli/classification , Escherichia coli/isolation & purification , Poultry Diseases/microbiology , Turkeys/microbiology , Animals , Bacterial Typing Techniques , Chromosomes, Bacterial , Cluster Analysis , DNA, Bacterial/genetics , Escherichia coli/genetics , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Female , Genotype , Humans , Male , Meningitis/microbiology , Phylogeny , Plasmids , Sequence Analysis, DNA , Serotyping , Urinary Tract Infections/microbiology , Virulence Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL